2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00383
    Rafigrelide 1029711-88-3
    Rafigrelide is a platelet-lowering agent, and also has antithrombotic properties.
    Rafigrelide
  • HY-101720A
    Fradafiban hydrochloride 99.96%
    Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
    Fradafiban hydrochloride
  • HY-103212A
    Azepexole hydrochloride 147663-20-5
    Azepexole hydrochloride (B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride) is a selective agonist for α 2-adrenoceptor, with pKi of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively. Azepexole dihydrochloride causes concentration-dependent inhibition of peristaltic contractions with IC50 of 78.72 nM. Azepexole hydrochloride exhibits antitussive and analgesic efficacy.
    Azepexole hydrochloride
  • HY-106688A
    Alinidine hydrobromide 71306-36-0 ≥99.0%
    Alinidine (St-567) hydrobromide is a specific bradycardic agent. Alinidine hydrobromide reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine hydrobromide shows antiischemic and antiarrhythmic effects.
    Alinidine hydrobromide
  • HY-106994A
    Nebentan potassium 342005-82-7 99.53%
    Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo.
    Nebentan potassium
  • HY-108795B
    [Gly8]-GLP-1(7-37) acetate 98%
    [Gly8]-GLP-1(7-37) acetate is a derivative of GLP-1 containing alanine-to-glycine substitution at positions 8. [Gly8]-GLP-1(7-37) acetate is also a peptide fragment of the GLP-1 receptor (GLP-1R) agonist Dulaglutide (HY-P0120).
    [Gly8]-GLP-1(7-37) acetate
  • HY-110397G
    KP-457 (GMP) 1365803-52-6 98%
    KP-457 (GMP) is KP-457 (HY-110397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture.KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC50s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.
    KP-457 (GMP)
  • HY-113147B
    L-Palmitoylcarnitine TFA ≥98.0%
    L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2.
    L-Palmitoylcarnitine TFA
  • HY-115748A
    Mant-GTPγS triammonium 98%
    Mant-GTPγS triammonium, a GTP mimetic, is a potent competitive adenylyl cyclase (AC) inhibitor. Mant-GTPγS triammonium is a potent YdeH inhibitor.
    Mant-GTPγS triammonium
  • HY-120355A
    AP14145 hydrochloride 2387505-59-9 98.3%
    AP14145 hydrochloride is a potent KCa2 (SK) channel negative allosteric modulator with an IC50 of 1.1 μM for KCa2.2 (SK2) and KCa2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel. AP14145 hydrochloride prolonged atrial effective refractory period (AERP) in rats and demonstrates antiarrhythmic effects in a Vernakalant-resistant porcine model of atrial fibrillation (AF).
    AP14145 hydrochloride
  • HY-120648A
    CAY 10462 dihydrochloride 502656-68-0 98.02%
    CAY 10434 dihydrochloride is a potent CYP4A hydroxylase inhibitor. CAY 10434 dihydrochloride improves contractile response to angiotensin II with the maximal contractile response (Emax) 6764 mg.
    CAY 10462 dihydrochloride
  • HY-121538A
    CUDA disodium 98%
    CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.
    CUDA disodium
  • HY-121936A
    Yohimbic acid hydrate 207801-27-2 99.96%
    Yohimbic acid hydrate is an amphoteric demethylated derivative of Yohimbine (HY-12715). Yohimbic acid hydrate exhibits vasodilatory action. Yohimbic acid hydrate also can be used for the research of osteoarthritis (OA).
    Yohimbic acid hydrate
  • HY-125989B
    2-Methylthio-AMP diTEA 1227193-98-7 ≥98.0%
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.
    2-Methylthio-AMP diTEA
  • HY-128090A
    Apstatin TFA 99.43%
    Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection.
    Apstatin TFA
  • HY-13955S3
    Telmisartan-d7 1794754-60-1 98%
    Telmisartan-d7 (BIBR 277-d7) is a deuterium labeled Telmisartan (HY-13955). Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
    Telmisartan-d7
  • HY-139573A
    (Rac)-Etavopivat 2622070-93-1 99.87%
    (Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat (HY-139573). Etavopivat is an orally active erythrocyte pyruvate kinase-R (PKR) activator that can be used in studies of sickle cell disease and other haemoglobinopathies.
    (Rac)-Etavopivat
  • HY-147079A
    Egaptivon pegol sodium
    Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.
    Egaptivon pegol sodium
  • HY-148144A
    Clobutinol hydrochloride 1215-83-4 99.22%
    Clobutinol hydrochloride is a compound that has anti-tussive effects. Clobutinol hydrochloride affects heart rate and blood pressure, it can be used for cough related research.
    Clobutinol hydrochloride
  • HY-14870S1
    Selexipag-d7 1265295-21-3 98.44%
    Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
    Selexipag-d7
Cat. No. Product Name / Synonyms Application Reactivity